N-(benzyl)aminoalkylcarboxylates, phosphinates, phosphonates and tetrazoles as Edg receptor agonists

A compound of Formula I

• or a pharmaceutically acceptable salt or hydrate thereof, wherein:
• Ar is phenyl;
• A is —CO2H;
• n is 2, 3 or 4;
• each R1 and R2 is independently selected from the group consisting of:
• hydrogen, halo, hydroxy, —CO2H, C1-6alkyl and phenyl, said C1-6alkyl and phenyl optionally substituted with 1-3 halo groups;
• R3 is selected from the group consisting of:
• hydrogen and C1-4alkyl, optionally substituted with 1-3 hydroxy or halo groups;
• each R4 is independently selected from the group consisting of:
• hydroxy, halo, —CO2H, C1-4alkyl, —S(O)kC1-3alkyl, wherein k is 0, 1 or 2, C1-3alkoxy, C3-6 cycloalkoxy, aryl and aralkoxy, the alkyl portions of said C1-4alkyl, —S(O)kC1-3alkyl, C1-3alkoxy and C3-6 cycloalkoxy optionally substituted with 1-3 halo groups;
• C is HET, wherein HET is thienyl;
• B is selected from the group consisting of:
• C1-6alkyl, C1-5alkoxy, —(C═O)—C1-5alkyl, —(C═O)—O—C1-4alkyl, —(C═O)—N(R6)(R7)—C1-4alkyl,
• phenyl and HET;
• and
• R6 and R7 are independently selected from the group consisting of:
• hydrogen, C1-9alkyl and —(CH2)p-phenyl, wherein p is 1 to 5 and phenyl is optionally substituted with 1-3 substituents independently selected from the group consisting of:
• C1-3alkyl and C1-3alkoxy, each optionally substituted with 1-3 halo groups.